(NASDAQ: RNA) Avidity Biosciences's forecast annual revenue growth rate of 168.31% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.22%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.95%.
Avidity Biosciences's revenue in 2024 is $10,870,000.On average, 1 Wall Street analysts forecast RNA's revenue for 2024 to be $2,373,704,085, with the lowest RNA revenue forecast at $2,373,704,085, and the highest RNA revenue forecast at $2,373,704,085. On average, 1 Wall Street analysts forecast RNA's revenue for 2025 to be $2,713,214,541, with the lowest RNA revenue forecast at $2,713,214,541, and the highest RNA revenue forecast at $2,713,214,541.
In 2026, RNA is forecast to generate $23,485,516,206 in revenue, with the lowest revenue forecast at $23,485,516,206 and the highest revenue forecast at $23,485,516,206.